Ester-Protected Vitamin K Derivatives for Stable Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vitamins K1 and K2 are unstable towards oxygen and light, leading to degradation, and their formulation with calcium or magnesium results in significant loss during tabletting, especially for MK-7, which is expensive and valuable.
Innovation Solution
Development of mono or disubstituted derivatives of vitamin K1 and K2, where the ketone functionalities are protected as esters, allowing for stability and reduced degradation when combined with calcium or magnesium salts, enabling more stable formulations and longer shelf life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If vitamin K1 and K2 are formulated with calcium or magnesium salts, then the nutritional value is enhanced, but significant degradation occurs during tabletting process
Solution Approach 1:
The patent applies preliminary action by converting vitamin K1 and K2 into their protected ester forms (prodrugs) before formulation. This preliminary chemical modification prevents degradation during subsequent processing steps. The esterified vitamins are then formulated with calcium/magnesium salts and processed into tablets, and finally undergo hydrolysis in the body to release the active vitamin K form, thus avoiding degradation during manufacturing while maintaining nutritional value.
Solution Approach 2:
The patent uses esterified vitamin K derivatives as intermediaries between the unstable vitamin K and the formulation process. These intermediary compounds are chemically modified to be stable during processing, serve as compatible excipients with calcium/magnesium salts, and can be converted back to active vitamin K in the physiological environment, thus mediating the conflict between stability and bioactivity.
2Reliability
If vitamin K2 is isolated from natural sources, then the authentic compound is obtained, but the process is complex and concentrations are low
Solution Approach 1:
The patent applies parameter changes by chemically modifying the molecular structure of vitamin K2 through esterification at the ketone functionalities. This changes the chemical parameters of the molecule to create stable prodrug forms that are easier to manufacture while maintaining the core naphthoquinone structure and biological activity. The synthesis starts from commercially available naphthoquinone derivatives, making the process more straightforward than natural isolation.
3Ease of operation
If vitamin K formulations are exposed to oxygen and light, then the vitamins perform their metabolic functions, but degradation occurs reducing shelf life
Solution Approach 1:
The patent applies preliminary anti-action by pre-protecting the vulnerable ketone functionalities of vitamin K1 and K2 through esterification before the vitamins are exposed to degrading conditions like oxygen and light during storage. This preliminary protective measure prevents oxidation and degradation reactions. The protection is reversible under physiological conditions, allowing the vitamins to perform their metabolic functions after administration while maintaining stability during storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protected vitamin K1 and K2 provitamins are more stable to light and air, exhibit lower degradation during processing, and can be formulated with calcium and magnesium without significant loss, offering improved storage stability and bioavailability.
Implementation Method 1
Analogues of vitamin K1 are of structure: (I) where R is -COCH2Ar, -COAr, -COC1-6alkyl group, -COH, or -CH(OH)Ar; each Ar is an optionally substituted phenyl or naphthyl group... The compounds are more stable than the vitamin itself in solution and when exposed to light and therefore have a longer shelf life.
Implementation Method 2
The present inventors have realised however, that vitamin K1 and especially K2 is not stable towards oxygen and light. Compositions containing vitamin K1 and K2 degrade. Racemisation of the double bonds in the isoprenoid chain leads to inactive vitamin K2 analogues for example, and these double bonds are obviously susceptible to oxidation. Also, the diketone itself is susceptible to oxidation in these vitamins.
Data Source
AI summary
This application relates to new formulations of vitamin K1 and K2 provitamins. These formulations can be used as nutraceuticals, e.g. for the fortification of foods or simply in supplements or can be used in pharmaceuticals for the treatment of a variety of conditions known to benefit from the administration of vitamin K1 and K2.